M402 => should we be watching Curis' GDC-0449 in pancreatic cancer? In this poster on M402, it is suggested that its MOA for reduction of primary tumor weight and metastases is through sonic hedgehog. Note the trial design for the first in human study -- which dosed its first patient this past week -- is also given. Data from part one will be out in 1H13, and it will simply be dose ranging & safety. Given the design, I'd guess that part two, which will have some efficacy data, will be out around mid to late 2014.
momentapharma.com
Folks talk similar talk for GDC-0449, which is also an inhibitor of SHH, and which is being trialed by several entities in pancreatic cancer, having been recently approved for advanced BCC. Data readouts should be coming steadily in advance of data for M402.
seekingalpha.com
I would guess the tox profiles are somewhat different for these two drugs. I don't think we know much yet about M402 in this regard, except to look for how well the anticoagulant properties have been engineered out. GDC-0449's SE profile (spasms, dysgeusia, alopecia, weight loss, joint pain, GI effects of various sorts, etc), can be seen here:
gene.com
Cheers, Tuck |
